| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Kenneth Van Heel is Director at ICU. Kenneth Van Heel's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $24K at current prices.
Historically, Kenneth Van Heel's trades have earned a below-average insider score of 20/100 across 3 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -68.7%.
Net of sales, the ICU filings show accumulation of 135,000 shares.
Kenneth Van Heel has 9 Form 4 filings on record from October 2022 to July 2026, all as Director at SeaStar Medical (ICU), 2022–2026.
The 13 reported transactions were 6 stock awards, 3 open-market purchases, 3 option or other derivative awards and 1 option exercise.
Counted by filing, the open-market trades come to 2 purchases worth about $71K and no sales.
The largest open-market purchase was 100,000 shares of ICU at an average $0.40 on November 22, 2023, about $40K. Twelve months later ICU was down 77%.